Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | PPIA | P62937 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28790534 | 0.86 | FFAR4 (0.54) | FFAR4FFAR1LMNAMAPTL3MBTL1 | |
| SCHEMBL4473413 | 0.86 | MAOB (0.61) | FFAR1LMNANPC1MAOBFOLH1 | |
| SCHEMBL28911191 | 0.85 | MCL1 (0.56) | FFAR4FFAR1LMNAMAPTL3MBTL1 | |
| SCHEMBL2999130 | 0.85 | SGMS2 (0.59) | LMNAMAPTL3MBTL1NPC1FOLH1 | |
| SCHEMBL30194507 | 0.85 | SGMS2 (0.59) | LMNAMAPTL3MBTL1NPC1FOLH1 | |
| SCHEMBL1106974 | 0.84 | PTGES (0.51) | LMNAMAOBLRRK2FOLH1PTGER1 | |
| SCHEMBL31605214 | 0.84 | PTGES (0.51) | LMNAMAOBLRRK2FOLH1PTGER1 | |
| SCHEMBL21436822 | 0.83 | MCL1 (0.55) | FFAR4FFAR1L3MBTL1MAOBFOLH1 | |
| SCHEMBL11355488 | 0.83 | PTGER1 (0.54) | NPC1MAOBLRRK2FOLH1PTGER1 | |
| SCHEMBL30956730 | 0.83 | MAOB (0.61) | FFAR4FFAR1LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-04-22 | — | — | US | disclosed |
| CN-111148731-B | Fluorophenyl beta-hydroxyethylamine and its use in the treatment of hyperglycaemia | 阿托基公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| EP-3681857-B1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3681857-B1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-4249054-A2 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2023-09-27 | — | — | EP | disclosed |
| EP-4249054-A2 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2023-09-27 | — | — | EP | disclosed |
| US-11648216-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2023-05-16 | — | — | US | disclosed |
| EP-3681857-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| CN-111148731-A | Fluorophenyl β -hydroxyethylamine and use thereof in the treatment of hyperglycaemia | 阿托基公司 | 2020-05-12 | — | — | CN | disclosed |
| WO-2019194582-A1 | METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO [2,3-F] CHROMENE DERIVATIVE | 주식회사 글라세움 | 2019-10-10 | — | — | WO | disclosed |
| WO-2019053426-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019053426-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-20060148817-A1 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1572664-A1 | PYRAZOLE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056782-A1 | PYRAZOLE COMPOUNDS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148817-A1 | Pyrazole compounds | NRAS, HSP90AB1, HSP90AA1 | FFAR4 4182/4885FFAR1 2336/4885LMNA 1845/4885 |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | FFAR4 232/4885FFAR1 241/4885LMNA 2098/4885 |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A2, SLC5A1 | FFAR4 232/4885FFAR1 241/4885LMNA 2098/4885 |
| US-11648216-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | FFAR4 232/4885FFAR1 241/4885LMNA 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.